New updates have been reported about Autoimmunity BioSolutions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Autoimmunity BioSolutions (ABS) is reinforcing its scientific credibility and platform strategy following the induction of company co-founder Dr. Mariano A. Garcia-Blanco into the U.S. National Academy of Sciences, one of the country’s highest scientific honors. ABS positions this recognition as validation of the foundational research underpinning its genetically guided immuno-corrective approach, which aims to normalize elevated levels of soluble IL7 receptor (sIL7R) in defined autoimmune patient subgroups.
The company’s platform is built on discoveries by Garcia-Blanco and co-founder Dr. Gaddiel Galarza-Munoz showing that a highly prevalent single nucleotide polymorphism, present in about half the population, drives a twofold to threefold increase in sIL7R expression, which has been consistently linked to greater disease severity, faster progression, and poor response to standard therapies across multiple autoimmune indications. ABS is targeting refractory patients—such as the roughly 50% of rheumatoid arthritis patients who respond inadequately to current standards of care—by selectively correcting sIL7R in those with the relevant genetic signature, with internal data indicating strong correlation between elevated sIL7R and non-response to agents like infliximab. Management frames this precision, pathway-specific strategy as a differentiated alternative to broad immunosuppression, with the potential to enhance response to existing therapies across autoimmune diseases and to create a defensible, biomarker-driven franchise, supported by Garcia-Blanco’s long-standing leadership in RNA biology, continuous NIH funding, and track record of translational entrepreneurship.